VELPHORO TABLET (CHEWABLE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

IRON (SUCROFERRIC OXYHYDROXIDE)

Pieejams no:

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD

ATĶ kods:

V03AE05

SNN (starptautisko nepatentēto nosaukumu):

SUCROFERRIC OXYHYDROXIDE

Deva:

500MG

Zāļu forma:

TABLET (CHEWABLE)

Kompozīcija:

IRON (SUCROFERRIC OXYHYDROXIDE) 500MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

30/90

Receptes veids:

Prescription

Ārstniecības joma:

PHOSPHATE-REMOVING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0108536040; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2018-01-05

Produkta apraksts

_ _
_Page 1 of 29_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
VELPHORO
®
Sucroferric Oxyhydroxide Chewable Tablet
500 mg iron (equivalent to 2500 mg sucroferric oxyhydroxide)
Phosphate Binder
Manufactured by:
Vifor Fresenius Medical Care Renal Pharma Ltd.
Rechenstrasse 37, 9014 St. Gallen
Switzerland
Imported by:
Otsuka Canada Pharmaceutical Inc.
Saint-Laurent, Quebec, H4S 2C9
Date of Initial Approval:
January 5, 2018
Date of Revision:
August 30, 2021
Submission Control No: 244717
_ _
_ _
_Page 2 of 29_
TABLE OF CONTENTS
TABLE OF
CONTENTS.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 4
1
INDICATIONS
...........................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................
4
3
DOSAGE AND ADMINISTRATION
.........................................................................
4
3.1
Dosing
Considerations.....................................................................................
4
3.2
Recommended Dose and Dosage Adjustment
.............................................. 4
3.3
Administration...................................................................................................
5
3.4
Missed
Dose.....................................................................................................
5
4
OVERDOSAGE
.........................................................................................................
5
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 5
6
WARNINGS AND
PRECAUTIONS.............................